BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28. [PMID: 18537181 DOI: 10.1002/hep.22336] [Cited by in Crossref: 272] [Cited by in F6Publishing: 243] [Article Influence: 19.4] [Reference Citation Analysis]
Number Citing Articles
1 Nobili V, Socha P. Pediatric Nonalcoholic Fatty Liver Disease: Current Thinking. Journal of Pediatric Gastroenterology & Nutrition 2018;66:188-92. [DOI: 10.1097/mpg.0000000000001823] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Licata A, Zerbo M, Como S, Cammilleri M, Soresi M, Montalto G, Giannitrapani L. The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement? Nutrients 2021;13:4014. [PMID: 34836267 DOI: 10.3390/nu13114014] [Reference Citation Analysis]
3 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
4 Yilmaz Y. Cytokeratins in hepatitis. Clin Chim Acta 2011;412:2031-6. [PMID: 21925155 DOI: 10.1016/j.cca.2011.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
5 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Arrigo T, Leonardi S, Cuppari C, Manti S, Lanzafame A, D’Angelo G, Gitto E, Marseglia L, Salpietro C. Role of the diet as a link between oxidative stress and liver diseases. World J Gastroenterol 2015; 21(2): 384-395 [PMID: 25593454 DOI: 10.3748/wjg.v21.i2.384] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
7 Murer SB, Aeberli I, Braegger CP, Gittermann M, Hersberger M, Leonard SW, Taylor AW, Traber MG, Zimmermann MB. Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents. J Nutr 2014;144:193-201. [PMID: 24353344 DOI: 10.3945/jn.113.185561] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
8 Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis. 2012;16:631-645. [PMID: 22824485 DOI: 10.1016/j.cld.2012.05.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
9 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 113] [Reference Citation Analysis]
10 Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619. [PMID: 21678341 DOI: 10.1002/14651858.cd003619.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
11 Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106:71-7. [PMID: 20842109 DOI: 10.1038/ajg.2010.299] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 14.3] [Reference Citation Analysis]
12 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
13 Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: Preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009; 15(48): 6017-6022 [PMID: 20027672 DOI: 10.3748/wjg.15.6017] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
14 Panera N, Barbaro B, Della Corte C, Mosca A, Nobili V, Alisi A. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. Nutrition Research 2018;58:1-16. [DOI: 10.1016/j.nutres.2018.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
15 Angulo P. Trial design in NASH—realities and challenges. Nat Rev Gastroenterol Hepatol 2011;8:424-5. [DOI: 10.1038/nrgastro.2011.125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Voican CS, Perlemuter G. Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol. 2011;54:388-391. [PMID: 21112115 DOI: 10.1016/j.jhep.2010.07.054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
17 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
18 Ratziu V. Management of nonalcoholic steatohepatitis: Pharmacotherapy. Clin Liver Dis (Hoboken) 2012;1:122-4. [PMID: 31186867 DOI: 10.1002/cld.74] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Volovelsky O, Weiss R. Fatty liver disease in obese children – relation to other metabolic risk factors. Int J Pediatr Obes 2011;6:59-64. [DOI: 10.3109/17477166.2011.583661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
20 Della Corte C, Carpino G, De Vito R, De Stefanis C, Alisi A, Cianfarani S, Overi D, Mosca A, Stronati L, Cucchiara S, Raponi M, Gaudio E, Byrne CD, Nobili V. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS One 2016;11:e0168216. [PMID: 27977757 DOI: 10.1371/journal.pone.0168216] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
21 Ma C, Liu Y, He S, Zeng J, Li P, Ma C, Ping F, Zhang H, Xu L, Li W, Li Y. Negative association between antioxidant vitamin intake and non-alcoholic fatty liver disease in Chinese non-diabetic adults: mediation models involving superoxide dismutase. Free Radic Res 2020;54:670-7. [PMID: 32985285 DOI: 10.1080/10715762.2020.1825705] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Liu HK, Hung TM, Huang HC, Lee IJ, Chang CC, Cheng JJ, Lin LC, Huang C. Bai-Hu-Jia-Ren-Shen-Tang Decoction Reduces Fatty Liver by Activating AMP-Activated Protein Kinase In Vitro and In Vivo. Evid Based Complement Alternat Med. 2015;2015:651734. [PMID: 26508982 DOI: 10.1155/2015/651734] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
23 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
24 Caldwell S, Lazo M. Is exercise an effective treatment for NASH? Knowns and unknowns. Annals of Hepatology 2009;8:S60-6. [DOI: 10.1016/s1665-2681(19)31828-9] [Cited by in Crossref: 26] [Article Influence: 2.0] [Reference Citation Analysis]
25 Lin M, Zeng H, Deng G, Lei J, Li J. Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101530. [PMID: 33272889 DOI: 10.1016/j.clinre.2020.08.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Chang TC, Chiang H, Lai YH, Huang YL, Huang HC, Liang YC, Liu HK, Huang C. Helminthostachys zeylanica alleviates hepatic steatosis and insulin resistance in diet-induced obese mice. BMC Complement Altern Med 2019;19:368. [PMID: 31836013 DOI: 10.1186/s12906-019-2782-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Ji G, Zhao X, Leng L, Liu P, Jiang Z. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis. 2011;10:23. [PMID: 21269482 DOI: 10.1186/1476-511X-10-23] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
28 Mazzone L, Postorino V, De Peppo L, Della Corte C, Lofino G, Vassena L, Fatta L, Armando M, Bedogni G, Vicari S, Nobili V. Paediatric non-alcoholic Fatty liver disease: impact on patients and mothers' quality of life. Hepat Mon 2013;13:e7871. [PMID: 23745129 DOI: 10.5812/hepatmon.7871] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
29 Wicklow B, Wittmeier K, T' Jong GW, McGavock J, Robert M, Duhamel T, Dolinsky VW. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol. Biochem Cell Biol 2015;93:522-30. [PMID: 26305052 DOI: 10.1139/bcb-2014-0136] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
30 Andrews DB, Lavine JE. Medical therapy for nonalcoholic fatty liver disease in children and adolescents. Expert Rev Gastroenterol Hepatol 2012;6:1-3. [PMID: 22149573 DOI: 10.1586/egh.11.72] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, Mohammadi M, Yari Z. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med 2020;52:102452. [PMID: 32951715 DOI: 10.1016/j.ctim.2020.102452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
32 Xanthakos SA, Kohli R. Treating Pediatric Nonalcoholic Fatty Liver Disease with Cysteamine: Is Adiponectin the Key? The Journal of Pediatrics 2012;161:579-81. [DOI: 10.1016/j.jpeds.2012.05.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
34 Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, Paolella G, Parenti G. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr. 2012;38:55. [PMID: 23075296 DOI: 10.1186/1824-7288-38-55] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
35 Hadzi-Petrushev N, Dimovska K, Jankulovski N, Mitrov D, Mladenov M. Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. Adv Pharmacol Sci 2018;2018:4673061. [PMID: 29887885 DOI: 10.1155/2018/4673061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Xu Y, Wu Y, Xiong Y, Tao J, Pan T, Tan S, Gao G, Chen Y, Abbas N, Getachew A, Zhuang Y, You K, Yang F, Li YX. Ascorbate protects liver from metabolic disorder through inhibition of lipogenesis and suppressor of cytokine signaling 3 (SOCS3). Nutr Metab (Lond) 2020;17:17. [PMID: 32158492 DOI: 10.1186/s12986-020-0431-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
38 Papandreou D, Karabouta Z, Pantoleon A, Rousso I. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease. Appetite 2012;59:939-44. [PMID: 23000278 DOI: 10.1016/j.appet.2012.09.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
39 Moshtaq MA, Rahimi MH, Mollahosseini M, Khorrami-nezhad L, Maghbooli Z, Mirzaei K, Pooyan S, Setayesh L. Association between dietary glycemic index and liver enzymes level among apparently healthy adults. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:1597-602. [DOI: 10.1016/j.dsx.2019.03.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
40 Seth A, Orkin S, Yodoshi T, Liu C, Fei L, Hardy J, Trout AT, Arce Clachar AC, Bramlage K, Xanthakos S, Mouzaki M. Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease. Pediatr Obes 2020;15:e12581. [PMID: 31657145 DOI: 10.1111/ijpo.12581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
41 Tveden-Nyborg P, Lykkesfeldt J. Does vitamin C deficiency increase lifestyle-associated vascular disease progression? Evidence based on experimental and clinical studies. Antioxid Redox Signal 2013;19:2084-104. [PMID: 23642093 DOI: 10.1089/ars.2013.5382] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
42 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
43 Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014; 20(2): 569-577 [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
44 Salameh N, Larrat B, Abarca-quinones J, Pallu S, Dorvillius M, Leclercq I, Fink M, Sinkus R, Van Beers BE. Early Detection of Steatohepatitis in Fatty Rat Liver by Using MR Elastography. Radiology 2009;253:90-7. [DOI: 10.1148/radiol.2523081817] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
45 Joshi D, Gupta N, Samyn M, Deheragoda M, Dobbels F, Heneghan MA. The management of childhood liver diseases in adulthood. Journal of Hepatology 2017;66:631-44. [DOI: 10.1016/j.jhep.2016.11.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
46 Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition. 2012;28:722-726. [PMID: 22464551 DOI: 10.1016/j.nut.2011.11.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
47 Rook M, Rosenthal P. Caring for adults with pediatric liver disease. Curr Gastroenterol Rep. 2009;11:83-89. [PMID: 19166664 DOI: 10.1007/s11894-009-0013-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
48 Xu L, Jiang CQ, Schooling CM, Zhang WS, Cheng KK, Lam TH. Liver enzymes and incident diabetes in China: a prospective analysis of 10 764 participants in the Guangzhou Biobank Cohort Study. J Epidemiol Community Health 2015;69:1040-4. [PMID: 26139641 DOI: 10.1136/jech-2015-205518] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
49 Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009;21:529-35. [PMID: 19444112 DOI: 10.1097/MOP.0b013e32832cb16f] [Cited by in Crossref: 58] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
50 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
51 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
52 Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 2013;65:952-968. [PMID: 23994574 DOI: 10.1016/j.freeradbiomed.2013.08.174] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 14.8] [Reference Citation Analysis]
53 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
54 Tzifi F, Fretzayas A, Chrousos G, Kanaka-Gantenbein C. Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease. Hormones (Athens) 2019;18:255-65. [PMID: 31140156 DOI: 10.1007/s42000-019-00107-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
55 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
56 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
57 Zhou J, Ho CT, Long P, Meng Q, Zhang L, Wan X. Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease. J Agric Food Chem 2019;67:5306-17. [PMID: 30892882 DOI: 10.1021/acs.jafc.8b05032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
58 Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282-1293. [PMID: 19637286 DOI: 10.1002/hep.23119] [Cited by in Crossref: 181] [Cited by in F6Publishing: 159] [Article Influence: 13.9] [Reference Citation Analysis]
59 Gibson PS, Lang S, Dhawan A, Fitzpatrick E, Blumfield ML, Truby H, Hart KH, Moore JB. Systematic Review: Nutrition and Physical Activity in the Management of Paediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2017;65:141-149. [PMID: 28737568 DOI: 10.1097/mpg.0000000000001624] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
60 Friesen CS, Hosey-Cojocari C, Chan SS, Csanaky IL, Wagner JB, Sweeney BR, Friesen A, Fraser JD, Shakhnovich V. Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy. Front Endocrinol (Lausanne) 2021;12:663351. [PMID: 33927697 DOI: 10.3389/fendo.2021.663351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Skrypnik D, Ratajczak M, Karolkiewicz J, Mądry E, Pupek-Musialik D, Hansdorfer-Korzon R, Walkowiak J, Jakubowski H, Bogdański P. Effects of endurance and endurance-strength exercise on biochemical parameters of liver function in women with abdominal obesity. Biomed Pharmacother 2016;80:1-7. [PMID: 27133033 DOI: 10.1016/j.biopha.2016.02.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
62 Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923-930. [PMID: 26059365 DOI: 10.1016/j.nut.2014.11.018] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 11.5] [Reference Citation Analysis]
63 Hadžić N, Baumann U, Mckiernan P, Mclin V, Nobili V. Long-term challenges and perspectives of pre-adolescent liver disease. The Lancet Gastroenterology & Hepatology 2017;2:435-45. [DOI: 10.1016/s2468-1253(16)30160-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
64 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
65 Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. ESPEN practical guideline: Clinical nutrition in liver disease. Clin Nutr 2020;39:3533-62. [PMID: 33213977 DOI: 10.1016/j.clnu.2020.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
66 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Barshop NJ, Francis CS, Schwimmer JB, Lavine JE. Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. Ped Health. 2009;3:271-281. [PMID: 20556232 DOI: 10.2217/phe.09.21] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
68 Corte CD, Iasevoli S, Strologo AD, Sanseviero M, Nobili V. Omega-3 Fatty Acids and Fatty Liver Disease in Children. Adv Food Nutr Res 2018;85:59-77. [PMID: 29860977 DOI: 10.1016/bs.afnr.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 Fleet SE, Lefkowitch JH, Lavine JE. Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America 2017;46:217-31. [DOI: 10.1016/j.gtc.2017.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
70 Draijer LG, van Oosterhout JPM, Vali Y, Zwetsloot S, van der Lee JH, van Etten-Jamaludin FS, Chegary M, Benninga MA, Koot BGP. Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review. Liver Int 2021;41:2087-100. [PMID: 33894100 DOI: 10.1111/liv.14908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Ramos-tovar E, Muriel P. Does Nutrition Matter in Liver Disease? Liver Pathophysiology. Elsevier; 2017. pp. 743-59. [DOI: 10.1016/b978-0-12-804274-8.00053-9] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
72 Kallwitz ER, Layden-Almer J, Dhamija M, Berkes J, Guzman G, Lepe R, Cotler SJ, Layden TJ. Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol. 2010;8:72-78. [PMID: 19686868 DOI: 10.1016/j.cgh.2009.08.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
73 Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res 2017;6:40. [PMID: 28503495 DOI: 10.4103/2277-9175.204593] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
74 Geiger R, Willeit J, Rummel M, Högler W, Stübing K, Strasak A, Geiger H, Stein JI, Rauchenzauner M. Six-Minute Walk Distance in Overweight Children and Adolescents: Effects of a Weight-Reducing Program. The Journal of Pediatrics 2011;158:447-51. [DOI: 10.1016/j.jpeds.2010.08.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
75 Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56:1171-1180. [PMID: 22245903 DOI: 10.1016/j.jhep.2011.09.024] [Cited by in Crossref: 253] [Cited by in F6Publishing: 243] [Article Influence: 25.3] [Reference Citation Analysis]
76 Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol 2009;43:565-8. [PMID: 19318980 DOI: 10.1097/MCG.0b013e31818f4fc2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
77 Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16:141-149. [PMID: 19262374 DOI: 10.1097/med.0b013e3283293015] [Cited by in Crossref: 114] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
78 Ko JS. New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History. Pediatr Gastroenterol Hepatol Nutr 2019;22:501-10. [PMID: 31777715 DOI: 10.5223/pghn.2019.22.6.501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
79 Chan DFY, So HK, Hui SCN, Chan RSM, Li AM, Sea MM, Chu WCW, Chan M, Woo J, Nelson EAS. Dietitian-led lifestyle modification programme for obese Chinese adolescents with non-alcoholic fatty liver disease: a randomized controlled study. Int J Obes (Lond) 2018;42:1680-90. [PMID: 29453464 DOI: 10.1038/s41366-018-0010-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
80 Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med. 2011;9:70. [PMID: 21645344 DOI: 10.1186/1741-7015-9-70] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
81 Manco M. Metabolic syndrome in childhood from impaired carbohydrate metabolism to nonalcoholic fatty liver disease. J Am Coll Nutr 2011;30:295-303. [PMID: 22081615 DOI: 10.1080/07315724.2011.10719972] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
82 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
83 Grønbæk H, Lange A, Birkebæk NH, Holland-fischer P, Solvig J, Hørlyck A, Kristensen K, Rittig S, Vilstrup H. Effect of a 10-week Weight Loss Camp on Fatty Liver Disease and Insulin Sensitivity in Obese Danish Children. Journal of Pediatric Gastroenterology & Nutrition 2012;54:223-8. [DOI: 10.1097/mpg.0b013e31822cdedf] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
84 El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel) 2018;7:E12. [PMID: 29337849 DOI: 10.3390/antiox7010012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
85 Beacher DR, Ariza AJ, Fishbein MH, Binns HJ. Screening for elevated risk of liver disease in preschool children (aged 2-5 years) being seen for obesity management. SAGE Open Med 2014;2:2050312114555211. [PMID: 26770745 DOI: 10.1177/2050312114555211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
86 Magkos F. Exercise and fat accumulation in the human liver: . Current Opinion in Lipidology 2010;21:507-17. [DOI: 10.1097/mol.0b013e32833ea912] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
87 Bozic MA, Subbarao G, Molleston JP. Pediatric Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2013;28:448-58. [DOI: 10.1177/0884533613489153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
88 Alisi A, Nobili V. Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way? Nat Rev Gastroenterol Hepatol 2011;8:425-6. [PMID: 21750513 DOI: 10.1038/nrgastro.2011.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
89 Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology. World J Gastroenterol 2010; 16(42): 5280-5285 [PMID: 21072890 DOI: 10.3748/wjg.v16.i42.5280] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
90 Kuo Y, Lin T, Chen W, Lee H. Alpha-lipoic acid induces adipose triglyceride lipase expression and decreases intracellular lipid accumulation in HepG2 cells. European Journal of Pharmacology 2012;692:10-8. [DOI: 10.1016/j.ejphar.2012.07.028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
91 Vajro P, Paolella G, Pierri L, D’Aniello R. Treatment of NASH with ursodeoxycholic acid: pros and cons. More information in children. Clin Res Hepatol Gastroenterol. 2013;37:e93-e94. [PMID: 23562789 DOI: 10.1016/j.clinre.2013.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013;52:165-74. [PMID: 23178552 DOI: 10.1016/j.plipres.2012.10.004] [Cited by in Crossref: 232] [Cited by in F6Publishing: 231] [Article Influence: 23.2] [Reference Citation Analysis]
93 Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16:517-30. [DOI: 10.1038/s41575-019-0169-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 21.7] [Reference Citation Analysis]
94 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
95 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1756-1767 [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
96 Crudele A, Panera N, Braghini MR, Balsano C, Alisi A. The pharmacological treatment of nonalcoholic fatty liver disease in children. Expert Rev Clin Pharmacol 2020;13:1219-27. [PMID: 32981386 DOI: 10.1080/17512433.2020.1829468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11:430-445. [PMID: 19845871 DOI: 10.1111/j.1467-789x.2009.00657.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
98 Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:616-629.e26. [PMID: 29913275 DOI: 10.1016/j.cgh.2018.06.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
99 Targher G, Bellis A, Fornengo P, Ciaravella F, Pichiri I, Cavallo Perin P, Trimarco B, Marchesini G. Prevention and treatment of nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:331-340. [PMID: 20207207 DOI: 10.1016/j.dld.2010.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
100 González Jiménez E, Schmidt Río-Valle J, Álvarez Ferre J. [Fatty liver and its clinical management in obese adolescents]. Endocrinol Nutr 2011;58:32-7. [PMID: 21216209 DOI: 10.1016/j.endonu.2010.10.005] [Reference Citation Analysis]
101 Caravatto PP, Cohen R. The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement. Curr Atheroscler Rep. 2017;19:45. [PMID: 28986720 DOI: 10.1007/s11883-017-0681-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
102 Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014;30:223-237. [PMID: 24717764 DOI: 10.1097/mog.0000000000000060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
103 Idilman IS, Keskin O, Elhan AH, Idilman R, Karcaaltincaba M. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease. Scand J Gastroenterol 2014;49:617-24. [PMID: 24694249 DOI: 10.3109/00365521.2014.894118] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
104 Huang WC, Liao PC, Huang CH, Hu S, Huang SC, Wu SJ. Osthole attenuates lipid accumulation, regulates the expression of inflammatory mediators, and increases antioxidants in FL83B cells. Biomed Pharmacother 2017;91:78-87. [PMID: 28448873 DOI: 10.1016/j.biopha.2017.04.051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
105 Haus JM, Solomon TP, Kelly KR, Fealy CE, Kullman EL, Scelsi AR, Lu L, Pagadala MR, McCullough AJ, Flask CA. Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013;98:E1181-E1188. [PMID: 23616151 DOI: 10.1210/jc.2013-1229] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
106 Perng W, Harte R, Ringham BM, Baylin A, Bellatorre A, Scherzinger A, Goran MI, Dabelea D. A Prudent dietary pattern is inversely associated with liver fat content among multi-ethnic youth. Pediatr Obes 2021;16:e12758. [PMID: 33296951 DOI: 10.1111/ijpo.12758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Nobili V, Mosca A, De Vito R, Raponi M, Scorletti E, Byrne CD. Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations. Liver Int 2018;38:1102-9. [PMID: 29222961 DOI: 10.1111/liv.13661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
108 Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology 2012;46:272-84. [DOI: 10.1097/mcg.0b013e31824587e0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
109 Ued Fda V, Weffort VR. Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents. Rev Paul Pediatr 2013;31:523-30. [PMID: 24473959 DOI: 10.1590/S0103-05822013000400016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Alberti G, Gana JC, Santos JL. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E3531. [PMID: 33212947 DOI: 10.3390/nu12113531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Gaborit B, Darmon P, Ancel P, Dutour A. Liraglutide for patients with non-alcoholic steatohepatitis. The Lancet 2016;387:2378-9. [DOI: 10.1016/s0140-6736(16)30734-6] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
112 Santoro R, Mangia A. Progress in promising anti-fibrotic therapies. Expert Rev Gastroenterol Hepatol 2019;13:1145-52. [PMID: 31692390 DOI: 10.1080/17474124.2019.1688659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
113 Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013;2013:450639. [PMID: 23653642 DOI: 10.1155/2013/450639] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
114 Moran-Lev H, Cohen S, Webb M, Yerushalmy-Feler A, Amir A, Gal DL, Lubetzky R. Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study. BMC Pediatr 2021;21:385. [PMID: 34479517 DOI: 10.1186/s12887-021-02839-1] [Reference Citation Analysis]
115 Lotfi A, Saneei P, Hekmatdost A, Salehisahlabadi A, Shiranian A, Ghiasvand R. The relationship between dietary antioxidant intake and physical activity rate with nonalcoholic fatty liver disease (NAFLD): A case - Control study. Clin Nutr ESPEN 2019;34:45-9. [PMID: 31677710 DOI: 10.1016/j.clnesp.2019.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
116 Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13:397-402. [PMID: 20531177 DOI: 10.1097/MCO.0b013e32833aae84] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
117 Uppal V, Mansoor S, Furuya KN. Pediatric Non-alcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2016;18:24. [PMID: 27086005 DOI: 10.1007/s11894-016-0498-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
118 Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J 2019;95:601-11. [PMID: 31434683 DOI: 10.1136/postgradmedj-2018-136364] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
119 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1902] [Article Influence: 205.7] [Reference Citation Analysis]
120 Chung MY, Yeung SF, Park HJ, Volek JS, Bruno RS. Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J Nutr Biochem. 2010;21:1200-1206. [PMID: 20138495 DOI: 10.1016/j.jnutbio.2009.10.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
121 Dey A, Lakshmanan J. The role of antioxidants and other agents in alleviating hyperglycemia mediated oxidative stress and injury in liver. Food Funct 2013;4:1148-84. [PMID: 23760593 DOI: 10.1039/c3fo30317a] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 8.9] [Reference Citation Analysis]
122 Ahmed IA, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. Saudi J Biol Sci 2019;26:1519-24. [PMID: 31762620 DOI: 10.1016/j.sjbs.2018.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
123 Annunziato RA, Rubes M, Davis C, Rose S, Arnon R. An Empirically Supported Framework for Addressing Pediatric Nonalcoholic Fatty Liver Disease in Outpatient Care. Cognitive and Behavioral Practice 2014;21:446-55. [DOI: 10.1016/j.cbpra.2014.07.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
124 Conjeevaram HS, Tiniakos DG. Exercise for NAFLD: Does Intensity Matter? American Journal of Gastroenterology 2011;106:470-5. [DOI: 10.1038/ajg.2010.496] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
125 Titmuss AT, Srinivasan S. Metabolic syndrome in children and adolescents: Old concepts in a young population. J Paediatr Child Health 2016;52:928-34. [PMID: 27301065 DOI: 10.1111/jpc.13190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
126 Garcovich M, Veraldi S, Di Stasio E, Zocco MA, Monti L, Tomà P, Pompili M, Gasbarrini A, Nobili V. Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. Radiology 2017;283:820-7. [PMID: 27982761 DOI: 10.1148/radiol.2016161002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
127 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659-1668. [PMID: 21521847 DOI: 10.1001/jama.2011.520.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Manco M, Bottazzo G, Devito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic Fatty Liver Disease in Children. Journal of the American College of Nutrition 2008;27:667-76. [DOI: 10.1080/07315724.2008.10719744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
129 Lefere S, Dupont E, De Guchtenaere A, Van Biervliet S, Velde SV, Verhelst X, Devisscher L, Van Vlierberghe H, Geerts A, De Bruyne R. Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01277-5. [PMID: 34871812 DOI: 10.1016/j.cgh.2021.11.039] [Reference Citation Analysis]
130 Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011;53:131-40. [PMID: 21629127 DOI: 10.1097/MPG.0b013e31822578db] [Cited by in Crossref: 50] [Cited by in F6Publishing: 81] [Article Influence: 4.5] [Reference Citation Analysis]
131 Diab L, Krebs NF. Vitamin Excess and Deficiency. Pediatrics in Review 2018;39:161-79. [DOI: 10.1542/pir.2016-0068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
132 Mouzaki M, Ling SC, Schreiber RA, Kamath BM. Management of Pediatric Nonalcoholic Fatty Liver Disease by Academic Hepatologists in Canada: A Nationwide Survey. J Pediatr Gastroenterol Nutr 2017;65:380-3. [PMID: 28333768 DOI: 10.1097/MPG.0000000000001581] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
133 Lu HF, Lai YH, Huang HC, Lee IJ, Lin LC, Liu HK, Tien HH, Huang C. Ginseng-plus-Bai-Hu-Tang ameliorates diet-induced obesity, hepatic steatosis, and insulin resistance in mice. J Ginseng Res 2020;44:238-46. [PMID: 32148405 DOI: 10.1016/j.jgr.2018.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
134 Tagi VM, Samvelyan S, Chiarelli F. Metabolic syndrome in children. Minerva Pediatr 2020;72:312-25. [PMID: 32274915 DOI: 10.23736/S0026-4946.20.05834-X] [Reference Citation Analysis]
135 Faienza MF, Chiarito M, Molina-Molina E, Shanmugam H, Lammert F, Krawczyk M, D'Amato G, Portincasa P. Childhood obesity, cardiovascular and liver health: a growing epidemic with age. World J Pediatr 2020;16:438-45. [PMID: 32020441 DOI: 10.1007/s12519-020-00341-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
136 Larion S, Khurana S. Clinical studies investigating the effect of vitamin E therapy in patients with NASH. Clin Liver Dis (Hoboken) 2018;11:16-21. [PMID: 30992781 DOI: 10.1002/cld.687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
137 Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, Chim AM, Chan CK, Leung JK, Chu WC, Woo J, Chan HL. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349-1356. [PMID: 30142427 DOI: 10.1016/j.jhep.2018.08.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
138 Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, Webb M, Shibolet O, Kariv R, Zelber-Sagi S. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig Liver Dis 2019;51:1698-705. [PMID: 31281067 DOI: 10.1016/j.dld.2019.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
139 Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65-S75. [PMID: 25920092 DOI: 10.1016/j.jhep.2015.02.041] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 28.3] [Reference Citation Analysis]
140 Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014; 20(45): 16831-16840 [PMID: 25492997 DOI: 10.3748/wjg.v20.i45.16831] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
141 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 53.1] [Reference Citation Analysis]
142 Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2013; 19(40): 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911] [Cited by in CrossRef: 195] [Cited by in F6Publishing: 174] [Article Influence: 21.7] [Reference Citation Analysis]
143 Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-1285. [PMID: 24738701 DOI: 10.1111/apt.12758] [Cited by in Crossref: 232] [Cited by in F6Publishing: 201] [Article Influence: 29.0] [Reference Citation Analysis]
144 Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79-104. [PMID: 20578268 DOI: 10.1002/hep.23623] [Cited by in Crossref: 370] [Cited by in F6Publishing: 343] [Article Influence: 30.8] [Reference Citation Analysis]
145 Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatr Drugs. 2018;20:315-329. [PMID: 29740791 DOI: 10.1007/s40272-018-0292-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
146 Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol 2019;13:447-61. [PMID: 30875479 DOI: 10.1080/17474124.2019.1595589] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
147 Hsu E, Murray K. Is nonalcoholic fatty liver disease in children the same disease as in adults? Clin Liver Dis 2012;16:587-98. [PMID: 22824482 DOI: 10.1016/j.cld.2012.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
148 Yang M, Gong S, Ye SQ, Lyman B, Geng L, Chen P, Li DY. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients 2014;6:4691-705. [PMID: 25353664 DOI: 10.3390/nu6114691] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
149 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 238] [Article Influence: 24.5] [Reference Citation Analysis]
150 Della Corte C, Liccardo D, Mosca A, Vania A, Nobili V. Non-alcoholic fatty liver disease. Paediatrics and Child Health 2013;23:529-34. [DOI: 10.1016/j.paed.2013.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Mann JP, Tang GY, Nobili V, Armstrong MJ. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Clinical Gastroenterology and Hepatology 2019;17:1457-1476.e7. [DOI: 10.1016/j.cgh.2018.05.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
152 Hannah WN, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1365-1374. [PMID: 27052013 DOI: 10.1007/s10620-016-4153-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
153 Alisi A, Manco M, Vania A, Nobili V. Pediatric Nonalcoholic Fatty Liver Disease in 2009. The Journal of Pediatrics 2009;155:469-74. [DOI: 10.1016/j.jpeds.2009.06.014] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
154 Lin M, Zhao S, Shen L, Xu D. Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition. Drug Saf 2014;37:213-24. [PMID: 24627311 DOI: 10.1007/s40264-014-0147-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
155 Goldschmidt I, Di Nanni A, Streckenbach C, Schnell K, Danne T, Baumann U. Improvement of BMI after Lifestyle Intervention Is Associated with Normalisation of Elevated ELF Score and Liver Stiffness in Obese Children. Biomed Res Int 2015;2015:457473. [PMID: 26273620 DOI: 10.1155/2015/457473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
156 Alisi A, Carpino G, Nobili V. Paediatric nonalcoholic fatty liver disease: . Current Opinion in Gastroenterology 2013;29:279-84. [DOI: 10.1097/mog.0b013e32835ff95e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
157 Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res. 2010;67:665-670. [PMID: 20496475 DOI: 10.1203/pdr.0b013e3181da4798] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
158 Feldstein AE, Patton-Ku D, Boutelle KN. Obesity, nutrition, and liver disease in children. Clin Liver Dis 2014;18:219-31. [PMID: 24274876 DOI: 10.1016/j.cld.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
159 Kohut T, Panganiban J. Lifestyle Intervention as the Primary Treatment for Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2021;17:185-90. [PMID: 33868663 DOI: 10.1002/cld.1022] [Reference Citation Analysis]
160 Nobili V, Vajro P, Dezsofi A, Fischler B, Hadzic N, Jahnel J, Lamireau T, McKiernan P, McLin V, Socha P. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr. 2015;60:550-561. [PMID: 25591123 DOI: 10.1097/mpg.0000000000000715] [Cited by in Crossref: 63] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
161 Rana H, Yadav SS, Reddy HD, Singhal S, Singh DK, Usman K. Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease. J Clin Diagn Res 2016;10:OC19-23. [PMID: 27656480 DOI: 10.7860/JCDR/2016/19887.8336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
162 Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr. 2014;173:131-139. [PMID: 24068459 DOI: 10.1007/s00431-013-2157-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
163 Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, Alavian SM. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One. 2011;6:e21178. [PMID: 21738618 DOI: 10.1371/journal.pone.0021178] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
164 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 1009] [Article Influence: 107.8] [Reference Citation Analysis]
165 Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20:143-153. [PMID: 24976277 DOI: 10.4103/1319-3767.132983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
166 D'Adamo E, Castorani V, Nobili V. The Liver in Children With Metabolic Syndrome. Front Endocrinol (Lausanne) 2019;10:514. [PMID: 31428049 DOI: 10.3389/fendo.2019.00514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
167 Mager DR, Iñiguez IR, Gilmour S, Yap J. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). JPEN J Parenter Enteral Nutr 2015;39:73-84. [PMID: 23976771 DOI: 10.1177/0148607113501201] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
168 Dong F, Zhang Y, Huang Y, Wang Y, Zhang G, Hu X, Wang J, Chen J, Bao Z. Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep 2016;6:36783. [PMID: 27830836 DOI: 10.1038/srep36783] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
169 DeVore S, Kohli R, Lake K, Nicholas L, Dietrich K, Balistreri WF, Xanthakos SA. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57:119-123. [PMID: 23518484 DOI: 10.1097/mpg.0b013e318290d138] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
170 Chiappini F, Desterke C, Bertrand-Michel J, Guettier C, Le Naour F. Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Sci Rep 2016;6:31587. [PMID: 27510159 DOI: 10.1038/srep31587] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
171 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
172 Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. Gastroenterology 2009;136:160-7. [DOI: 10.1053/j.gastro.2008.09.013] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 13.3] [Reference Citation Analysis]
173 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
174 Yodoshi T, Orkin S, Arce-Clachar AC, Bramlage K, Su W, Fei L, Xanthakos SA, Mouzaki M. Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis. JPEN J Parenter Enteral Nutr 2020;44:1301-7. [PMID: 31985850 DOI: 10.1002/jpen.1766] [Reference Citation Analysis]
175 Mărginean CO, Meliț LE, Săsăran MO. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic. Biomedicines 2021;9:1866. [PMID: 34944682 DOI: 10.3390/biomedicines9121866] [Reference Citation Analysis]
176 Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D, Gaudio E. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology. 2012;56:2142-2153. [PMID: 22467277 DOI: 10.1002/hep.25742] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 10.0] [Reference Citation Analysis]
177 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Role of Vitamin E in the Treatment of NAFLD. Diseases 2018;6:E86. [PMID: 30249972 DOI: 10.3390/diseases6040086] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
178 Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan HL. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2013;59:536-542. [PMID: 23623998 DOI: 10.1016/j.jhep.2013.04.013] [Cited by in Crossref: 154] [Cited by in F6Publishing: 155] [Article Influence: 17.1] [Reference Citation Analysis]
179 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 343] [Article Influence: 36.6] [Reference Citation Analysis]
180 Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012;9:152-61. [DOI: 10.1038/nrgastro.2011.273] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
181 Ong JP, Younossi ZM. Editorial: probiotics in NASH - more studies are needed. Aliment Pharmacol Ther. 2014;40:211-212. [PMID: 24946062 DOI: 10.1111/apt.12812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68. [PMID: 21521847 DOI: 10.1001/jama.2011.520] [Cited by in Crossref: 662] [Cited by in F6Publishing: 582] [Article Influence: 60.2] [Reference Citation Analysis]
183 Deboer MD, Wiener RC, Barnes BH, Gurka MJ. Ethnic differences in the link between insulin resistance and elevated ALT. Pediatrics. 2013;132:e718-726. [PMID: 23940240 DOI: 10.1542/peds.2012-3584] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
184 Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34. [PMID: 28107283 DOI: 10.1097/MPG.0000000000001482] [Cited by in Crossref: 306] [Cited by in F6Publishing: 133] [Article Influence: 76.5] [Reference Citation Analysis]
185 Betancourt-Garcia MM, Arguelles A, Montes J, Hernandez A, Singh M, Forse RA. Pediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children. Obes Surg. 2017;27:236-244. [PMID: 27822768 DOI: 10.1007/s11695-016-2440-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
186 Conlon BA, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 2013;5:4093-4114. [PMID: 24152749 DOI: 10.3390/nu5104093] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
187 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
188 Zöhrer E, Alisi A, Jahnel J, Mosca A, Della Corte C, Crudele A, Fauler G, Nobili V. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab 2017;42:948-54. [PMID: 28511023 DOI: 10.1139/apnm-2016-0689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
189 Fusillo S, Rudolph B. Nonalcoholic fatty liver disease. Pediatr Rev. 2015;36:198-205; quiz 206. [PMID: 25934909 DOI: 10.1542/pir.36-5-198] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
190 Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol 2020;13:1756284820974917. [PMID: 33335561 DOI: 10.1177/1756284820974917] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
191 Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, Jung DH, Kim KH, Yu E, Shim JH, Lim YS, Lee HC, Chung YH, Lee Y, Suh DJ. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol. 2012;27:1341-1347. [PMID: 22554085 DOI: 10.1111/j.1440-1746.2012.07165.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
192 Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:E947. [PMID: 27314342 DOI: 10.3390/ijms17060947] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
193 Ode KL, Frohnert BI, Nathan BM. Identification and treatment of metabolic complications in pediatric obesity. Rev Endocr Metab Disord 2009;10:167-88. [PMID: 19809879 DOI: 10.1007/s11154-009-9115-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
194 Lin C, Kohli R. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-00786-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016;95:e4529. [PMID: 27512874 DOI: 10.1097/md.0000000000004529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
196 Watt KD. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl. 2012;18 Suppl 2:S52-S58. [PMID: 22821716 DOI: 10.1002/lt.23515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
197 Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011; 17(26): 3082-3091 [PMID: 21912450 DOI: 10.3748/wjg.v17.i26.3082] [Cited by in F6Publishing: 54] [Reference Citation Analysis]
198 Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease: Treatment of NAFLD. International Journal of Clinical Practice 2010;64:968-83. [DOI: 10.1111/j.1742-1241.2009.02327.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
199 Alkhouri N, Carter-Kent C, Elias M, Feldstein AE. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol. 2011;6:305-314. [PMID: 22162978 DOI: 10.2217/clp.11.19] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
200 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
201 Said A. Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances. World J Gastroenterol 2013; 19(48): 9146-9155 [PMID: 24409043 DOI: 10.3748/wjg.v19.i48.9146] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
202 Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology 2012;55:1292-5. [PMID: 22461076 DOI: 10.1002/hep.24767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
203 Raza S, Tewari A, Rajak S, Sinha RA. Vitamins and non-alcoholic fatty liver disease: A Molecular Insight. Liver Res 2021;5:62-71. [PMID: 34221537 DOI: 10.1016/j.livres.2021.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
204 Ipsen DH, Tveden-Nyborg P, Lykkesfeldt J. Does vitamin C deficiency promote fatty liver disease development? Nutrients 2014;6:5473-99. [PMID: 25533004 DOI: 10.3390/nu6125473] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
205 Nath P, Panigrahi MK, Sahu MK, Narayan J, Sahoo RK, Patra AA, Jena S, Patnaik AK, Jena A, Singh SP. Effect of Exercise on NAFLD and Its Risk Factors: Comparison of Moderate versus Low Intensity Exercise. J Clin Transl Hepatol 2020;8:120-6. [PMID: 32832391 DOI: 10.14218/JCTH.2019.00012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
206 Nobili V, Svegliati-baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology 2013;58:1218-29. [DOI: 10.1016/j.jhep.2012.12.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 11.8] [Reference Citation Analysis]
207 Pacifico L, Anania C, Martino F, Poggiogalle E, Chiarelli F, Arca M, Chiesa C. Management of metabolic syndrome in children and adolescents. Nutrition, Metabolism and Cardiovascular Diseases 2011;21:455-66. [DOI: 10.1016/j.numecd.2011.01.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
208 Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, Onori P, Gaudio E. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014;9:e88005. [PMID: 24505350 DOI: 10.1371/journal.pone.0088005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 11.0] [Reference Citation Analysis]
209 Wei J, Lei GH, Fu L, Zeng C, Yang T, Peng SF. Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults. PLoS One 2016;11:e0147985. [PMID: 26824361 DOI: 10.1371/journal.pone.0147985] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
210 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
211 Denzer C. [Non-alcoholic fatty liver disease in obese children and adolescents]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56:517-27. [PMID: 23529597 DOI: 10.1007/s00103-012-1639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
212 Bugianesi E, Bizzarri C, Rosso C, Mosca A, Panera N, Veraldi S, Dotta A, Giannone G, Raponi M, Cappa M, Alisi A, Nobili V. Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology 2017;112:1277-86. [DOI: 10.1038/ajg.2017.140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
213 Guillaume M, Ratziu V. Pharmacological agents for nonalcoholic steatohepatitis. Hepatol Int 2013;7 Suppl 2:833-41. [PMID: 26202298 DOI: 10.1007/s12072-013-9482-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
214 Nobili V, Alisi A, Mosca A, Crudele A, Zaffina S, Denaro M, Smeriglio A, Trombetta D. The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment? Antioxid Redox Signal 2019;31:127-33. [PMID: 30588836 DOI: 10.1089/ars.2018.7704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
215 Carpino G, Nobili V, Renzi A, De Stefanis C, Stronati L, Franchitto A, Alisi A, Onori P, De Vito R, Alpini G, Gaudio E. Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. PLoS One. 2016;11:e0157246. [PMID: 27310371 DOI: 10.1371/journal.pone.0157246] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
216 Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1155-1170. [PMID: 25267322 DOI: 10.1111/apt.12972] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
217 Torun E, Gökçe S, Ozgen İT, Aydın S, Cesur Y. Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents. J Pediatr Endocrinol Metab 2014;27:667-75. [PMID: 24706428 DOI: 10.1515/jpem-2013-0337] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
218 Manco M, Mosca A, De Peppo F, Caccamo R, Cutrera R, Giordano U, De Stefanis C, Alisi A, Baumann U, Silecchia G, Nobili V. The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. The Journal of Pediatrics 2017;180:31-37.e2. [DOI: 10.1016/j.jpeds.2016.08.101] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
219 Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51:305-312. [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
220 Manco M, Alisi A, Nobili V. Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. Hepatology. 2008;48:2087-2088; author reply 2088. [PMID: 18980229 DOI: 10.1002/hep.22631] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
221 Ben Hsouna A, Dhibi S, Dhifi W, Ben Saad R, Brini F, Hfaidh N, Almeida JRGDS, Mnif W. Lobularia maritima leave extract, a nutraceutical agent with antioxidant activity, protects against CCl 4 -induced liver injury in mice. Drug and Chemical Toxicology. [DOI: 10.1080/01480545.2020.1742730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
223 Mcneice K, Sandberg K. Updates in non-alcoholic fatty liver disease (NAFLD). Current Problems in Pediatric and Adolescent Health Care 2020;50:100844. [DOI: 10.1016/j.cppeds.2020.100844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Xanthakos SA, Kohli R. Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management. Clin Liver Dis (Hoboken) 2012;1:125-8. [PMID: 31186868 DOI: 10.1002/cld.75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Caro-Sabido EA, Larrosa-Haro A. Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity: A scoping review. Rev Gastroenterol Mex (Engl Ed) 2019;84:185-94. [PMID: 31101468 DOI: 10.1016/j.rgmx.2019.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
226 Koot BG, van der Baan-Slootweg OH, Vinke S, Bohte AE, Tamminga-Smeulders CL, Jansen PL, Stoker J, Benninga MA. Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment. Int J Obes (Lond) 2016;40:51-7. [PMID: 26315844 DOI: 10.1038/ijo.2015.175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
227 Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;60:360-367. [PMID: 25714579 DOI: 10.1097/mpg.0000000000000584] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
228 Nobili V, Carpino G, De Peppo F, Caccamo R, Mosca A, Romito I, Overi D, Franchitto A, Onori P, Alisi A, Gaudio E. Laparoscopic Sleeve Gastrectomy Improves Nonalcoholic Fatty Liver Disease-Related Liver Damage in Adolescents by Reshaping Cellular Interactions and Hepatic Adipocytokine Production. J Pediatr 2018;194:100-108.e3. [PMID: 29198531 DOI: 10.1016/j.jpeds.2017.10.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
229 Shephard RJ, Johnson N. Effects of physical activity upon the liver. Eur J Appl Physiol 2015;115:1-46. [DOI: 10.1007/s00421-014-3031-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
230 Perito ER, Rodriguez LA, Lustig RH. Dietary treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2013;29:170-6. [PMID: 23283181 DOI: 10.1097/MOG.0b013e32835ca11d] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
231 Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008;48:442-8. [PMID: 18563842 DOI: 10.1002/hep.22376] [Cited by in Crossref: 266] [Cited by in F6Publishing: 239] [Article Influence: 19.0] [Reference Citation Analysis]
232 Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJG, Freeman SC, Cooper NJ, Sutton AJ, Fritche D, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;6:CD013156. [PMID: 34114650 DOI: 10.1002/14651858.CD013156.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
233 Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085-2091.e1. [PMID: 24815326 DOI: 10.1016/j.cgh.2014.04.038] [Cited by in Crossref: 150] [Cited by in F6Publishing: 148] [Article Influence: 18.8] [Reference Citation Analysis]
234 Deldin AR, Lee S. Role of physical activity in the treatment of nonalcoholic fatty liver disease in children and adolescents. Appl Physiol Nutr Metab 2013;38:805-12. [DOI: 10.1139/apnm-2012-0503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
235 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 239] [Article Influence: 21.4] [Reference Citation Analysis]
236 Wei J, Shi M, Wu WQ, Xu H, Wang T, Wang N, Ma JL, Wang YG. IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice. World J Gastroenterol 2011; 17(47): 5203-5213 [PMID: 22215946 DOI: 10.3748/wjg.v17.i47.5203] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
237 Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol 2014; 20(34): 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
238 Neuschwander-tetri BA. Lifestyle Modification as the Primary Treatment of NASH. Clinics in Liver Disease 2009;13:649-65. [DOI: 10.1016/j.cld.2009.07.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
239 Hattar LN, Wilson TA, Tabotabo LA, Smith EO, Abrams SH. Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol 2011; 17(39): 4396-4403 [PMID: 22110265 DOI: 10.3748/wjg.v17.i39.4396] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
240 Della Corte C, Alisi A, Iorio R, Alterio A, Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opin Pharmacother. 2011;12:1901-1911. [PMID: 21639814 DOI: 10.1517/14656566.2011.587123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
241 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 395.6] [Reference Citation Analysis]
242 Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011;5:279-89. [PMID: 21476922 DOI: 10.1586/egh.11.19] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
243 Nobili V, Sanyal AJ. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2012;47:29-36. [PMID: 21983927 DOI: 10.1007/s00535-011-0467-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
244 Utz-Melere M, Targa-Ferreira C, Lessa-Horta B, Epifanio M, Mouzaki M, Mattos AA. Non-Alcoholic Fatty Liver Disease in Children and Adolescents: Lifestyle Change - a Systematic Review and Meta-Analysis. Ann Hepatol 2018;17:345-54. [PMID: 29735796 DOI: 10.5604/01.3001.0011.7380] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
245 Nobili V, Reale A, Alisi A, Morino G, Trenta I, Pisani M, Marcellini M, Raucci U. Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. Digestive and Liver Disease 2009;41:749-52. [DOI: 10.1016/j.dld.2009.02.048] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
246 Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J, Leng L, Jiang Z. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol. 2011;11:762-768. [PMID: 21320636 DOI: 10.1016/j.intimp.2011.01.036] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
247 Pirgon Ö, Bilgin H, Çekmez F, Kurku H, Dündar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol. 2013;5:33-39. [PMID: 23367495 DOI: 10.4274/jcrpe.825] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
248 Della Pepa G, Vetrani C, Lombardi G, Bozzetto L, Annuzzi G, Rivellese AA. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Nutrients 2017;9:E1065. [PMID: 28954437 DOI: 10.3390/nu9101065] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
249 Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes 2013;2013:839275. [PMID: 23431426 DOI: 10.1155/2013/839275] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 8.2] [Reference Citation Analysis]
250 Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017;83:88-95. [PMID: 26852185 DOI: 10.1111/bcp.12899] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
251 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
252 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]